Sandoz: commercial launch of Pyzchiva in US
(CercleFinance.com) - Sandoz announces the commercial launch, in the US, of Pyzchiva, a biosimilar for the treatment of certain chronic inflammatory diseases, with the same indications as its reference drug, Johnson & Johnson's Stelara.
The Swiss group says that Pyzchiva strengthens its immunology portfolio and increases access to biologics for US patients suffering from chronic inflammatory diseases, such as psoriasis and psoriatic arthritis
Meeting a variety of patient needs, Pyzchiva offers a full range of dosing options and extended stability, including the ability to be refrigerated, compared to the reference drug, it adds.
Under the terms of the agreement with Samsung Bioepis, which developed this biosimilar, Sandoz has the right to market Pyzchiva in the United States, Canada, the EEA, Switzerland, the UK and Brazil.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
The Swiss group says that Pyzchiva strengthens its immunology portfolio and increases access to biologics for US patients suffering from chronic inflammatory diseases, such as psoriasis and psoriatic arthritis
Meeting a variety of patient needs, Pyzchiva offers a full range of dosing options and extended stability, including the ability to be refrigerated, compared to the reference drug, it adds.
Under the terms of the agreement with Samsung Bioepis, which developed this biosimilar, Sandoz has the right to market Pyzchiva in the United States, Canada, the EEA, Switzerland, the UK and Brazil.
Copyright (c) 2025 CercleFinance.com. All rights reserved.